

Lee D Cranmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6123082/publications.pdf>

Version: 2024-02-01

18
papers

355
citations

1040056

9
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

810
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3299-3306.	1.6	132
2	<p>Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2047-2062.	2.0	35
3	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 31-41.e4.	1.9	31
4	Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 22.	4.1	25
5	Pazopanib in the management of advanced soft tissue sarcomas. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 941.	2.0	23
6	Chemotherapy in Esthesioneuroblastoma/Olfactory Neuroblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 203-209.	1.3	18
7	Identification and quantitation of clinically relevant microbes in patient samples: Comparison of three k-mer based classifiers for speed, accuracy, and sensitivity. <i>PLoS Computational Biology</i> , 2019, 15, e1006863.	3.2	17
8	Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells. <i>Clinical Cancer Research</i> , 2022, 28, 1701-1711.	7.0	17
9	Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis. <i>Clinical Orthopaedics and Related Research</i> , 2022, 480, 748-758.	1.5	14
10	Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma. <i>JAMA Oncology</i> , 2022, 8, 740.	7.1	12
11	Long-term Outcomes for Extraskeletal Myxoid Chondrosarcoma: A SEER Database Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2351-2357.	2.5	8
12	Targeting gastrointestinal stromal tumors: the role of regorafenib. <i>OncoTargets and Therapy</i> , 2016, 9, 3009.	2.0	5
13	Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients. <i>Cancers</i> , 2022, 14, 1290.	3.7	5
14	Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 446-451.	1.3	4
15	Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. <i>Cancer Investigation</i> , 2021, 39, 1-6.	1.3	4
16	FÃ©dÃ©ration Nationale Des Centres de Lutte Contre Le Cancer (FNCLCC) Grading, Margin Status and Tumor Location Associate With Survival Outcomes in Malignant Peripheral Nerve Sheath Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 28-35.	1.3	3
17	An Openâ€Label, Randomized, Multiâ€Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukinâ€2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. <i>Oncimmunology</i> , 2021, 10, 1984059.	4.6	2
18	Combination Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcomaâ€Reply. <i>JAMA Oncology</i> , 2021, 7, 465.	7.1	0